Upcoming Medical Policies BlueCross BlueShield of Tennessee

Each medical policy listed below will become effective on the date indicated, and will be included in the Medical Policy Manual for BlueCross BlueShield of Tennessee on that effective date.

Medical policies are developed using an evidence-based evaluation process.  The medical evidence used in this process comes from several sources, including independent medical technology review organizations, the peer reviewed medical literature, and opinions from appropriate network specialists. All Medical Policies are reviewed by a panel of internal and external physicians before being adopted by the company.

Topics due to be included in the Medical Policy Manual on 6/11/2013

Topics due to be included in the Medical Policy Manual on 7/13/2013

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Topics due to be included in the Medical Policy Manual on 6/11/2013:

Implantable Sinus Spacers and Stents

Interferential Current Stimulation

Interspinous Fixation (Fusion) Devices

Non-invasive Prenatal Testing Using Cell-free Fetal DNA (cffDNA)

Pertuzumab

Taliglucerase Alfa

Topics due to be included in the Medical Policy Manual on 6/12/2013:

Peginesatide

Topics due to be included in the Medical Policy Manual on 7/13/2013:

Eyelid Thermal Pulsation

Gene Expression Profiling Assays as a Technique to Determine Prognosis for Managing Breast Cancer Treatment

Intravenous Immune Globulin (IVIG) Therapy

Nerve Fiber Density Testing

Radiofrequency Ablation for Treatment of Tumors

Last Review Date8 5/16/2013